This study was supported by a grant from the Ministry of Health, Labour and Welfare of Japan.
Replaced platelet concentrates containing a new additive solution, M-sol: safety and efficacy for pediatric patients
Version of Record online: 17 DEC 2012
© 2012 American Association of Blood Banks
Volume 53, Issue 9, pages 2053–2060, September 2013
How to Cite
Yanagisawa, R., Shimodaira, S., Kojima, S., Nakasone, N., Ishikawa, S., Momose, K., Honda, T., Yoshikawa, K., Saito, S., Tanaka, M., Nakazawa, Y., Sakashita, K., Shiohara, M., Akino, M., Hirayama, J., Azuma, H. and Koike, K. (2013), Replaced platelet concentrates containing a new additive solution, M-sol: safety and efficacy for pediatric patients. Transfusion, 53: 2053–2060. doi: 10.1111/trf.12025
- Issue online: 9 SEP 2013
- Version of Record online: 17 DEC 2012
- Manuscript Revised: 30 OCT 2012
- Manuscript Accepted: 30 OCT 2012
- Manuscript Received: 9 APR 2012
Allergic transfusion reactions (ATRs), particularly those caused by plasma-rich platelet concentrates (P-PCs), are an important concern in transfusion medicine. Replacing P-PCs with PCs containing M-sol (M-sol-R-PCs) is expected to prevent ATRs. However, this has not yet been verified by sufficient clinical evidence.
Study Design and Methods
A retrospective cohort study was performed between 2008 and 2011. Pediatric patients with hematologic disorders, solid tumors, primary immunodeficiency disorders, or inherited metabolic disorders were transfused with M-sol-R-PCs between 2010 and 2011; the transfusions of P-PCs administered between 2008 and 2011 were compared in terms of frequency and severity of ATRs, corrected count increment (CCI), and occurrence of bleeding. Data were collected for 6 consecutive months on a per-patient basis.
Data obtained during 2008 to 2011 showed that of the 78 patients receiving 515 P-PC transfusions, 14 (17.9%) had 17 ATRs (3.3%); 14 and three ATRs were of Grades 1 and 2, respectively. In 2010 to 2011, 49 patients received 620 transfusions of M-sol-R-PCs, and two patients (4.1%) had Grade 1 ATRs (0.3%). Thus, the frequency of ATRs per bag and per patient differed significantly between the two transfusions. No steroid agents were used for the prevention or treatment of ATRs in the M-sol-R-PC group. The CCI (24 hr) for M-sol-R-PCs did not differ from that for P-PCs.
M-sol-R-PCs were found to be effective in preventing ATRs without loss of transfusion efficiency in children; however, its efficacy should be further evaluated in prospective clinical trials.